Hans Hammers, MD, PhD

Articles

Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

December 1st 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.

Dr. Hammers on Combination of Vaccines and Immune Checkpoint Inhibitors in RCC

May 5th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Dr. Hammers Discusses Immunotherapy in RCC

March 2nd 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).

Dr. Hammers on Study of HyperAcute Renal Immunotherapy in RCC

February 17th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

Dr. Hammers on Nivolumab/Ipilimumab Data in RCC

January 7th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses a mature data set regarding nivolumab and ipilimumab in the treatment of patients with renal cell carcinoma.